Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDIA6 | Q15084 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480614 | 0.81 | PDE4B (0.43) | PDIA6MCHR1PTGS2PDE4B | |
| SCHEMBL12970780 | 0.81 | ALDH1A1 (0.54) | PDIA6MCHR1PTGS2PDE4BALDH1A1 | |
| SCHEMBL13624065 | 0.80 | MAPK1 (0.41) | MRGPRX4NR1H4EPHX2ALDH1A1LPAR1 | |
| SCHEMBL13634528 | 0.79 | MAPT (0.43) | MCHR1PTGS2PDE4B | |
| SCHEMBL15180036 | 0.79 | CA1 (0.39) | MCHR1PTGS2PDE4BALDH1A1 | |
| SCHEMBL9957748 | 0.77 | ALDH1A1 (0.59) | NR1H4EPHX2ALDH1A1LPAR1 | |
| SCHEMBL13889421 | 0.77 | MEN1 (0.44) | MCHR1PTGS2PDE4B | |
| SCHEMBL13624143 | 0.77 | NQO1 (0.45) | MRGPRX4NR1H4EPHX2ALDH1A1 | |
| SCHEMBL13624071 | 0.75 | LMNA (0.36) | MRGPRX4NR1H4EPHX2ALDH1A1LPAR1 | |
| SCHEMBL12970679 | 0.75 | PARP15 (0.55) | PDE4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | PDIA6 814/4885MCHR1 4718/4885PTGS2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.